R&D Governance, Controlling and Innovation for Pharma

Pharma R&D leaders in Europe are facing a rare convergence of pressures: a historic patent cliff, tightening EU/UK pricing and HTA reforms, and growing geopolitical and regulatory complexity. These forces are reshaping how portfolios are constructed, how programs are funded, and how capital is allocated across platforms, modalities, and therapeutic areas. Traditional portfolio optimization and PPM events do not go far enough, because they rarely address investment governance, decision quality, and execution capacity as core design questions.

The Marcus Evans R&D Governance, Controlling and Innovation for Pharma conference taking place on 21-23 September 2026, at Crowne Plaza - Frankfurt Congress Hotel, will focus on how pharma R&D leaders can redesign decision‑making, governance and operating models to improve development success, portfolio productivity and probability of success under revenue disruption, pricing reform and intensifying regulatory and competitive pressure in Europe. Sessions will explore evidence‑driven kill criteria, portfolio and platform prioritisation, build‑versus‑buy and divestiture choices, and the integration of regulatory, reimbursement and market‑access realities earlier in investment decisions, including how to reflect EU HTA and country‑specific pricing constraints in R&D capital allocation.

Attending This Premier Marcus Evans Conference Will Enable You to:

Rebalance pharma R&D investment to protect pipeline value under patent and market pressure
Improve pharma R&D productivity to strengthen investment and development decisions
Sharpen R&D stop, continue and reprioritisation decisions to reduce late-stage attrition
Improve R&D data quality and predictive metrics to support better development and portfolio decisions
Optimise build, buy and partner decisions to improve pharma R&D pipeline value
Strengthen translational evidence to reduce Phase II investment risk

Best Practices and Case Studies from:

Paul Jeannin, Global Head of R&D Controlling Operations, Sanofi
Shane Cowley, Director, Portfolio Analytics and Decision Science, Novartis
Christophe De Vleeschouwer, Director, Pipeline Project Management R&D,, GSK
Fabio Baschiera, Head of Global Clinical Development Eye Health, Boehringer Ingelheim
Nishaban Talukdar, Director, R&D IT - E2E R&D, Operations Management, AstraZeneca
Joan Toftegaard Boesen, Senior Director, R&D Finance, Novo Nordisk

pharmaphorum members are entitled to a €200 discount! For more information, please contact Ria Kiayia, Digital Media & PR Marketing Manager, Marcus Evans, at riak@marcusevanscy.com or visit https://bit.ly/4689Bfy